What is AC Immune SA (ACIU)?
AC Immune SA is a biopharmaceutical company specializing in the development of therapies for neurodegenerative diseases. The company focuses on targeting protein misfolding and aggregation, which are implicated in conditions such as Alzheimer's disease and other related disorders. Utilizing a proprietary platform, AC Immune aims to create diagnostic tools and therapeutic candidates that address the underlying causes of these diseases. The company engages in both internal research and collaborations with other pharmaceutical entities to advance its pipeline. Its operations include clinical development, biomarker discovery, and immunotherapy approaches. AC Immune is headquartered in Switzerland and operates within the biotechnology sector, contributing to the broader field of neurodegenerative disease research and treatment development.
AC Immune SA Stock Price Today: Live Overview
The price today is shaped by the latest trading activity, with Schwab Intermediate-Term U.S. Treasury ETF currently at $2.91. The intraday range has been between $2.85 and $3, reflecting a daily change of +1.7606%.
FAQ: AC Immune SA (ACIU)
What is the current price of ACIU stock?
The current price stands at $2.91.
Does ACIU pay dividends?
Dividends are not paid by the company.
Does ACIU have a formal corporate presence or regional headquarters in the UAE?
AC Immune SA does not have an official regional office or subsidiary in the UAE and operates through international partnerships.
What is ACIU best known for?
The company is most famous for its development of therapies targeting neurodegenerative diseases.
What assets are typically shown together with ACIU?
Commonly shown alongside ACIU: Virbac SA, Invesco S&P 500 Equal Weight UCITS ETF, PICC Property
Latest shares articles



